New vaginal insert could block HIV and herpes
NCT ID NCT06087913
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This early-stage study tested a vaginal insert containing two anti-HIV drugs (tenofovir alafenamide and elvitegravir) in 68 healthy women. The insert was used daily for 3 days then every other day for 14 days. The goal was to check safety and how the drugs are absorbed, as a first step toward an on-demand prevention method for HIV and HSV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CAPRISA eThekwini Clinical Research Site
Durban, South Africa
-
Eastern Virginia Medical School Clinical Research Clinic (EVMS CRC)
Norfolk, Virginia, 23507, United States
-
Kenya Medical Research Institute (KEMRI)
Thika, Kenya
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tenofovir alafenamide and elvitegravir vaginal insert
What this could lead to
If successful, this could lead to a new on-demand method for preventing HIV and HSV infection during sex.
What could go wrong
This is an early Phase 1 safety study with only 68 participants, so it cannot yet prove the insert prevents infection. The results may not lead to an effective product.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.